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ORIGINAL RESEARCH ARTICLE
Dominant immunosuppression of dendritic cell function by
prostate-cancer-derived exosomes
Josephine Salimu*, Jason Webber, Mark Gurney , Saly Al-Taei, Aled Clayton and Zsuzsanna Tabi
Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK
ABSTRACT
Exosomes are a distinct population of extracellular vesicles of endocytic origin with a protein
repertoire similar to the parent cell. Although tumour-derived exosomes harbour immunosuppres-
sive characteristics, they also carry tumour antigens and thus potentially contribute to immune
activation. The aim of this study was to examine the impact of prostate cancer exosomes on tumour
antigen cross-presentation. DU145 cells, transduced with shRNA to knockdown Rab27a (DU145KD)
that inhibits exosome secretion, triggered significantly stronger tumour-antigen-specific T cell
responses when loaded onto dendritic cells (DC) than control DU145 cells. Enhanced T cell response
was prevented by adding purified exogenous DU145 exosomes to DU145KD cells, demonstrating
that the dominant effect of tumour exosomes is immunosuppression and not antigen delivery.
CD8+ T cell responses were impaired via exosomal regulation of DC function; exosomes triggered
the expression of CD73, an ecto-5-nucleotidase responsible for AMP to adenosine hydrolysis, on
DC. CD73 induction on DC that constitutively express CD39 resulted in an ATP-dependent inhibi-
tion of TNFα- and IL-12-production. We identified exosomal prostaglandin E2 (PGE2) as a potential
driver of CD73 induction, as inhibition of PGE2 receptors significantly reduced exosome-dependent
CD73 induction. The results reveal a hitherto unknown suppression of DC function via exosomal
PGE2, adding a new element to tumour exosome–immune cell cross-talk.
Abbreviations: AMP: adenosine monophosphate; ATP: adenosine triphosphate; BLCL: B lympho-
blastoid cell line; CME: exosomes enriched from cell line conditionedmedia; DC: dendritic cell; DMSO:
dimethyl-sulfoxide; DU145C: DU145 cells with irrelevant knockdown control; DU145KD: DU145 cells
with Rab27a knockdown; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; GM-
CSF: granulocyte-monocyte colony stimulating factor; HLA: human lymphocyte antigen; IL: interleu-
kin; LPS: lipopolysaccharide; mfi: mean fluorescence intensity; PBMC: peripheral blood mononuclear
cells; PBS: phosphate buffer solution; PGE2: prostaglandin E2; TRF: time-resolved fluorescence.
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Introduction
Cancer cells influence tumour-infiltrating immune cells
mainly via cell-to-cell contact and soluble factors.
However, accumulating evidence indicates an immune-
regulatory role for tumour-derived microvesicles, known
as “exosomes” [1]. Exosomes are a distinct population of
membranous vesicles of endocytic origin. They range from
30 to 150 nm in diameter and are released by cells upon
fusion of intracellular multivesicular bodies with the
plasma membrane [2].
Exosomes express a protein repertoire similar to that
of the cell of origin. This results in the formation of
functionally diverse exosomes, capable of immune acti-
vation or immune suppression, respectively. Tumour-
derived exosomes harbour the immunosuppressive
characteristics of tumour cells [3]. These exosomes
can directly impair the capacity of CD14+ monocytes
to differentiate into functional dendritic cells (DC),
thus having a potential effect on both antigen presenta-
tion and subsequent T cell responses [4]. Tumour-
derived exosomes have also been shown to generate
myeloid-derived suppressor cells in mice [5].
Furthermore, tumour-derived exosomes may induce
apoptosis of activated tumour-specific T cells [6],
impair the cytotoxicity, activation and proliferation of
lymphocytes [7–9] and generate regulatory T cells [10].
On the other hand, as tumour-derived exosomes carry
tumour antigens, they may contribute to antigen cross-
presentation by DC to initiate antitumour immune
responses [11,12]. Tumour antigen cross-presentation
occurs when antigen-presenting cells take up, process and
present extracellular tumour antigens on MHC class I
molecules to CD8+ T cells. We have previously shown
that irradiated prostate cancer cells (DU145), expressing
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the 5T4 tumour-associated antigen, are taken up by DC,
which then efficiently cross-present the antigen to 5T4-
specific CD8+ T cells that kill 5T4+ tumour cells [13].
The aim of this study was to examine whether antigen
transfer or immunosuppression is the dominant effect of
exosomes during tumour antigen cross-presentation. In
order to answer this question, we developed a DU145
prostate cancer cell line where Rab27a, a key mediator of
exosome release from the cell [14], had been knocked
down (DU145KD). We found an immunosuppressive
effect of exosomes during tumour antigen cross-presenta-
tion, mediated by CD73 induction on DC. The resulting
net effect of exosomes was adenosine-mediated immuno-
suppression. The findings of this study will greatly con-
tribute to our understanding of the role exosomes play in
tumour–immune cell cross-talk in cancer.
Materials and methods
Tumour cells
DU145 prostate cancer cells were obtained from the
American Type Culture Collection and maintained
in culture with regular passaging for less than
6 months. Authentication was carried out by the
supplier using cytogenetic, isoenzymatic and DNA
profile analysis. The HLA type of DU145 cells is
HLA-A03/A33/B50/B57 (Welsh Blood Transfusion
Service, Cardiff, UK). The cells were mycoplasma
free and tested regularly using a MycoAlert
Mycoplasma Detection Kit (LT07-418; Lonza).
Irradiation was carried out using a 137Cs-source
(with regular dosimetry quality assurance) at a rate
of 0.627 Gy/min.
Media, reagents and inhibitors
RPMI-1640 (BE12-167F; Lonza) was supplemented with
fetal bovine serum (10270106; Thermo Fisher Scientific),
AB-serum (H4522; Sigma-Aldrich) where indicated,
100 U/ml penicillin, 100 mg/ml streptomycin (DE17-
603E; Lonza), 2 mmol/l L-glutamine (BE17-605E; Lonza),
25 mmol/l HEPES and 1 mmol/l sodium pyruvate (Sigma-
Aldrich). FBS was depleted of bovine exosomes by pellet-
ing at 100,000 g for 2 h. Lipopolysaccharide (LPS, L4391),
ATP (A6419) and AMP-CP (CD73 inhibitor, M8386)
were obtained from Sigma. PGE2, (2292), NECA (1691)
and SCH58261 (adenosine A2A receptor inhibitor, 2270)
were obtained from Tocris. PGE2-receptor inhibitors AH-
6809 (EP2 inhibitor; CAY14050) and AH-23848 (EP4
inhibitor; CAY-19023) were obtained from Cayman
Chemicals.
Rab27a lentiviral knockdown
Briefly, DU145 cells were plated in 48-well flat-bottomed
plates at 18,000 cells/well. On day one, cells were infected
with lentiviral particles, at a multiplicity of infection = 10,
delivering Rab27a or non-mammalian control shRNA
(SHCLNV; Sigma-Aldrich) in the presence of hexadi-
methrine bromide (8 mg/ml, H9268; Sigma-Aldrich).
Puromycin (1.25 mg/ml, P9620, Sigma-Aldrich) was
added on day 2. Media were changed on day 5, and cells
were cultured in the presence of puromycin for a further
six passages prior to experimental use. Rab27a expression
was quantified by qRT-PCR (Applied Biosystems; Thermo
Fisher Scientific), and expressed relative to the control
cells. Exosome secretion was measured by nanoparticle
tracking analysis (Nanosight, Malvern Instruments,
Amesbury, UK) as described [15] and confirmed by
immunofluorescence-based quantification of exosomes.
Exosome enrichment from conditioned media of
cell lines
Culture media was collected from confluent cultures of
DU145C or DU145KD cells. The cells were trypsined and
counted. Themedia were subjected to serial centrifugation,
at 400 g for 7 min to remove cells and at 2000 g for 15 min
to remove any non-cellular debris. A filtration step using a
0.22 µm membrane filter was also carried out to remove
any fragments and vesicles larger than 200 nm. The super-
natant was then centrifuged at 200,000 g for 2 h, to pellet
the microvesicles. These exosome-containing pellets were
resuspended in fresh culture media, normalized to original
cell numbers (in 7 ml/107 cells). We refer to them as
“exosomes enriched from conditioned media” (CME) in
this paper. CME preparations, derived from the two cell
lines, were added at 50% to T cells or DC.
Exosome purification
Exosome purification was performed as we have pre-
viously described [16]. Briefly, prostate cancer cell condi-
tioned media was subjected to serial centrifugation to
remove cells (400 g, 10 min) and cellular debris (2000 g,
15 min). The supernatant was then filtered (0.22 μm), to
remove remaining debris and larger vesicles. The clarified
media was underlaid with a 4 ml cushion of 30% sucrose/
D2O (S9378; 151882; Sigma-Aldrich), and following 2 h
ultracentrifugation at 100,000 g (SW32 rotor; Beckman
Coulter), the cushion was collected, and washed in excess
PBS (BE17-512F; Lonza) by ultracentrifugation. The pel-
let was resuspended in 50–100 μl PBS and frozen in
aliquots at −80°C. Protein concentrations were evaluated
using a micro-BCA protein assay (23235; Thermo); the
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nanoparticles in each preparation were quantified by
nanoparticle tracking analysis (see above).
Use of CellGS-Exo-Spin Midi Columns
Exo-Spin Midi Columns (EX04; Cell Guidance Systems)
were pre-packed in a preservative-containing buffer. This
buffer was removed and the columns were washed twice
with 20 ml of PBS. Cell conditioned medium (1 ml),
freshly defrosted at room temperature, was added to the
column prior to elution with PBS, and up to 30 separate
500 µl fractions were collected. A proportion of each
fraction was assayed using a micro-BCA protein assay,
CD81 protein binding assay and PGE2 competitive
enzyme immunoassay (KGE004B; R&D Systems).
Analysis of column fractions by immunostaining
Immunostaining was performed as previously described
[17]. Briefly, 50 µl of each fraction was diluted 1:1 with
PBS and then added to high-binding enzyme-linked
immunosorbent assay (ELISA) strips (756071; Greiner
Bio-One Ltd). After overnight incubation at 4°C, the
plates were washed three times in wash buffer (42-01;
Kaivogen Oy) using an automated plate washer (Thermo
Fisher Scientific), and blocked for 2 h at room tempera-
ture using 1% bovine serum albumin (DY995; R&D
Systems) in PBS. Plates were then washed as above, and
primary antibodies added at 1 µg/ml. These included
anti-CD81 (MCA1847EL; AbD Serotec) and isotype con-
trols (14-4714-85; e-Bioscience). After 2 h at room tem-
perature, the strips were washed, and goat anti-mouse
IgG-biotin conjugated antibody was added (1:2500;
NEF823001EA; Perkin Elmer) and incubated for an
hour. After another wash, a streptavidin-europium con-
jugate was added (1:1000; 1244-360; PerkinElmer) in red
assay buffer (42-01; Kaivogen Oy) and incubated for
40–60 min. The strips were washed six times prior to
addition of europium fluorescent intensifier (42-04;
Kaivogen Oy), and time-resolved fluorescence (TRF)
was performed on a PHERAstar FS multi-mode plate
reader (BMG Labtech).
Donors and DC
Ethical approval to collect venous blood was granted and
informed consent was obtained from healthy HLA-A2+
volunteers. Peripheral blood mononuclear cells (PBMC)
from venous blood, collected in EDTA vacutainers, were
isolated by density gradient centrifugation. CD14+mono-
cytes were enriched by negative selection using the
EasySep Human Monocyte Enrichment Kit without
CD16 Depletion (19058; StemCell Technologies).
Average purity of CD14+ cells was 70–80%, determined
by flow cytometry (CD14 antibody from Affymetrix,
25-0149). Cells were incubated at 5 × 106 cells per well
in 6-well trays in 5 ml/well of 10% FBS-RPMI plus
500 ng/ml rhGM-CSF (CYT-221; ProSpec) and 500 U/
ml IL-4 (Gentaur) for 5–6 days. DC were exposed either
to purified exosomes at 200 μg/ml for 48 h or to CME at
50% of culture media, unless otherwise indicated.
Generation of a 5T4 specific CD8+ T-cell line
A CD8+ T-cell line was developed from a HLA-A2+
healthy donor by repeated stimulation of nonadherent
PBMCs with autologous DC loaded with 2 mg/ml 5T4
[17–25] peptide (RLARLALVL; ProImmune), as
described previously [18].
Flow cytometry
Cells were labelled in flow cytometry buffer (PBS, 1mmol/l
EDTA and 2% FBS) with fluorochrome-conjugated anti-
bodies and incubated on ice for 40 min. For intracellular
labelling, the cells were fixed and permeabilized using
e-Bioscience Fixation (00-82249) and Permeabilization
(00-8333) reagents before antibodies were added for
40 min at room temperature. Antibodies used in this
study: CD73 (550257, BD Bioscience), CD14 as above,
CD39 (17-0399, e-Bioscience), 5T4 (FAB49751F, R&D).
For cytokine flow cytometry, T cells were fixed and per-
meabilized as above and CD3 (47-0036), CD8 (45-0088)
and IFNγ (12-7319) antibodies (e-Bioscience) were added
together for 40 min. Flow cytometry was carried out using
a FACSVerse flow cytometer with FACSuite software (BD
Bioscience).
T cell and DC stimulation
Primary T cell stimulation. Untouched T cells were sepa-
rated from PBMCusing the EasySep T cell enrichment kit
(19051; StemCell Technologies). Tumour cells (104/well)
or enriched exosomes (CME) were added for 45 min
before adding CD3/CD28 antibody coated beads to T
cells (105/well) (11131D; Thermo Fisher Scientific) at
1:1 bead : T cell ratio. Overnight cytokine flow cytometry
for IL-2 production was carried out, or IL-2 was detected
in the supernatant after 24 h stimulation by ELISA.
Antigen cross-presentation assays were carried out by
plating out DU145 cells in two 96-well U-bottomed plates
(5 × 103 cells/well). After irradiating one plate with 12 Gy,
plates were incubated for 72 h. DC were then added at
5 × 103 to the wells and, after 48 h, 5T4-specific CD8+ T
cells were added at 2.5 × 104 cells/well. Golgi Plug (0.2 µl/
200 µl; 55509; BD) and Golgi Stop (0.14 µl/200 µl; 554724;
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BD) were added to the wells 1 h later and the cultures
were incubated overnight. Cytokine flow cytometry was
carried out to determine the percentage of IFNγ+CD8+ T
cells [13].
Peptide stimulation assay of 5T4-specific T cells was
carried out by loading autologous DC with the 5T4 pep-
tide (20 μg/ml) for 1 h, adding 105 T cells to 104 DC in an
overnight cytokine flow cytometry assay as described.
The following treatments were also carried out before
co-culturing T cells and DC: (a) T cells were pre-treated
with NECA (0.5–2 μM) for 1 h; (b) CD73 inhibitor
(10 μM) and/or A2AR inhibitor (10 μM) were added for
1 h and the excess removed; DC were pre-treated with
PGE2 receptor inhibitors EP2 and EP4 (100 μM each) for
30min. AMP (200 μM)was added to DC 30min before T
cells were added.
LPS stimulation of DC, co-cultured with 100 μg/ml
exosomes for 24 h, was carried out with or without
40 μMATP added for 30min. This was followed by adding
200 ng/ml LPS in the presence of 100 ng/ml IFNγ for 18 h.
Cytokine flow cytometry to detect IL-12 (554575, BD) and
TNFα (17-7349, e-Bioscience) produced by DC was car-
ried out as above.
IL-2 ELISA
The IL-2 Duo-Set ELISA kit was purchased from R&D
Systems (DY202). T cell supernatants were harvested
after 24 h culture and kept at −20°C before assaying
them according to the manufacturer’s instructions.
Statistical analysis
Statistical analysis was carried out by applying Student’s
t-test, paired t-test and ANOVAwith Tukey’s post-hoc test
(GraphPad InStat 3.06). Statistically significant differences
are marked as *p < 0.05; **p < 0.01; ***p < 0.001.
Results
Knockdown of Rab27a decreases exosome
secretion by DU145 cells
In order to assess the influence of exosomes on tumour
antigen cross-presentation, we generated aDU145 prostate
cancer cell line with deficient exosome secretion, by knock-
ing down Rab27a [14] using lentiviral particles.
(DU145KD) Quantification by qPCR and western blotting
revealed 80% reduction in Rab27a expression at both
mRNA and protein level, compared to that of the
DU145C control cell line. Knockdown efficiency was vali-
dated at different passage numbers to verify long-term
stable gene silencing (Figure 1(a)). To establish if knocking
down Rab27a expression successfully inhibited the secre-
tion of particles ranging from 30 to 150 nm in diameter,
which we will call here “exosomes”, nanoparticle tracking
analysis was carried out (Figure 1(c), i and ii). Particle
secretion by the DU145KD cell line was less then 30% of
that secreted by the DU145C cell line (Figure 1(c), ii).
Immunofluorescence-based quantification of exosomes
confirmed a similar level of reduction in exosome release
by DU145KD cells (Figure 1(c), ii).
DU145KD cells induce superior T cell responses
To study the effect of tumour-derived exosomes on
antigen cross-presentation, we used a previously estab-
lished antigen cross-presentation model [13]. Irradiated
(12Gy) or untreated DU145KD and DU145C cells were
co-cultured with HLA-A2+ DC followed by co-culture
with tumour-antigen-specific T cells. A 5T4-specific,
HLA-A2-restricted CD8+ T cell line was used and the
percentage of T cells producing IFNγ upon stimulation
with these DC was determined. DC co-cultured with
DU145KD cells generated significantly stronger T cell
responses than those co-cultured with DU145C cells
when the tumour cells received no radiation. The results
(Figure 2(a)) show that inhibition of exosome secretion is
beneficial for this immune response. In contrast, cross-
presentation from 12Gy irradiated DU145C and
DU145KD cell lines generated similar levels of T cell
responses (Figure 2(a)). We established that 5T4 antigen
expression levels were comparable in the two untreated
cell lines and upregulated at a similar extent by irradiation
in both lines (Figure 2(b)). To confirm whether it was the
lack of exosomes that influenced T cell responses in the
cross-presentation of antigen from non-irradiated cells,
exosomes were added back to DC together with
DU145KD cells at 200 µg/ml. The addition of exosomes
together with DU145KD cells to DC reduced T cell
responses to the same level as induced by DU145C cells
(Figure 2(c)). This confirms that the presence of tumour
exosomes dampens T cell responses during tumour anti-
gen cross-presentation from prostate cancer cells.
Exosomes inhibit IL-2 production by CD4+ but not
CD8+ T cells
Wehave previously reported that exosomes directly inhibit
IL-2 production by T cells, preferentially by CD4+ T cells
[7,9]. Here we wanted to examine the extent to which
exosomes directly affect T cell function in the cross-pre-
sentationmodel. First, freshly isolated primary T cells were
co-cultured with DU145C and DU145KD cells before sti-
mulation with CD3/CD28 antibody-coated beads for 24 h
(Figure 3). IL-2 ELISA of the supernatant indicated that IL-
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D
ow
nl
oa
de
d 
by
 [C
ard
iff
 U
niv
ers
ity
 L
ibr
ari
es
] a
t 0
3:4
7 0
4 S
ep
tem
be
r 2
01
7 
a b
c
Figure 1. Knockdown of Rab27a decreases exosome secretion by DU145 cells. (a) Rab27a expression at mRNA level at 12 and 22
passages in DU145KD cells. Relative expression compared with that in DU145C cells shown. (b) Rab27a protein levels detected by
western blotting in DU145 cells. (c) Exosome secretion, measured by nanoparticle tracking analysis (i, ii) or by an in-house exosome
ELISA-like assay (iii). (a, c) ii and iii: Raw data are shown as symbols; means + SE are also shown. ***p < 0.001, **p < 0.01.
Representatives of at least three repeat experiments are shown.
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Figure 2. Exosomes inhibit antigen cross-presentation. (a) 5T4-specific T cells were stimulated overnight in the cross-presentation
model, as shown. (b) 5T4 expression (mfi) is shown on DU145 cells with or without irradiation after 48 h culture. Representatives of
two to three repeated experiments are shown. (c) T cells as in (a), DC were loaded with non-irradiated DU145 cells with or without
exosomes, as indicated. Raw data are shown as symbols; means + SD of results are also shown. *p < 0.05, **p < 0.01.
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2 production by T cells was comparable when stimulated
with beads alone orwith beads in the presence ofDU145KD
cells. Conversely, 50% less IL-2 was detected in response to
beads in the presence of DU145C cells, confirming the
direct immunosuppressive effects of exosomes on T cells
(Figure 3(a)). Next, we wanted to confirm whether exo-
somes were able to elicit the same immunosuppressive
effects in both CD4+ and CD8+ T cell subsets. This objec-
tive was achieved by using exosomes enriched by serial
centrifugation of the supernatants from DU145C and
DU145KD cell cultures. These exosome preparations
reflected the exosome concentrations of the conditioned
media from the two cell lines (CME). Significantly more
CD4+ T cells produced IL-2 in the presence of DU145KD
CME, compared with DU145C, while CD8+ T cells were
not sensitive to the presence of exosomes (Figure 3(b)).
This suggests that the impact of exosomes on the function
of 5T4-specific CD8+ T cells in the cross-presentation assay
is distinct from the observed and published direct effect of
exosomes on CD4+ T cells.
Exosomes induce CD73 expression on DCs
Next, we studied whether exosomes have exerted any
immune-regulatory effects on antigen-presenting cells,
as this may indirectly lead to impaired CD8+ T cell
responses. DC were co-cultured with tumour cells or
exosome fractions from the control and knockdown cell
lines for 48 h before assessing the expression of immu-
nosuppressive markers. DC treatment with both cell lines
or with exosomes from both cell lines resulted in the
induction of CD73 on DC. The percentage of
CD39+CD73+ cells and the mean fluorescence intensity
(mfi) of CD73 expression on DC (Figure 4(a)) were
significantly higher in the presence of DU145C cells and
CME than in the presence of DU145KD cells and
DU145KD CME. This was confirmed with DC from
three different donors (Figure 4(b)). CD73 induction on
DC proved to be exosome dose dependent (Figure 4(c)),
which explains the less efficient CD73 induction by
DU145KD cells. As it has been previously shown that
exosomes express membrane-bound CD73 [7], we
wanted to confirm that CD73 expression on DC was
not due to exosome binding. To do this, expression of
CD73 and the exosome marker CD9 were assessed on
DC, treated for 24 h with or without exosomes, by flow
cytometry (Figure 4(d)). While the presence of exosomes
induced expression of surface CD73 on DC, the level of
CD9 expression remained unchanged, indicating that
CD73 expression was independent of exosome attach-
ment to the cell surface. Furthermore, blocking protein
synthesis by pre-treating DC for 30 min before adding
exosomes with cyclohexamide decreased CD73 induction
(Figure 4(e)), proving that CD73 expression onDC is not,
or at least not exclusively, the result of these cells being
“decorated” by CD73-expressing exosomes binding or
adhering to DC.
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Figure 3. Direct effect of exosomes on T cell function. Primary T cells were stimulated with CD3/CD28 antibody-coated beads in the
presence of (a) DU145C or DU145KD cells or (b) DU145C or DU145KD CME. (a) IL-2 secretion 24 h after T cell stimulation was
measured by ELISA. (b) Intracellular cytokine staining of percentage of IL-2+ CD4+ and CD8+ T cells after an overnight incubation
with CD3/CD28 beads in the presence CME preparations, as shown. Raw data are shown as symbols; means + SD of results are also
shown. *p < 0.05, **p < 0.01. Representatives of two repeated experiments are shown.
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two to three repeated experiments are shown. (c) DC treated with increasing concentrations or with (d) 200 µg/ml purified DU145
exosomes. Raw data are shown as symbols. Means + SD of CD73 or CD9 expression are also shown. (e) DC pre-treated with
increasing concentrations of cyclohexamide (CHX) before exosome treatment. CD73 expression is shown from triplicate samples
(mean + SD). *p < 0.05, **p < 0.01, ***p < 0.001.
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Exosomal PGE2 contributes to CD73 induction on DC
We were interested in establishing the mechanism of exo-
some-induced CD73 expression on DC. As it has been
shown in our laboratory recently that PGE2 induces CD73
on primary CD14+ cells [19], we tested whether PGE2 was
contributing to the induction of CD73 on DC. DC treat-
ment for 24 h with PGE2 (50 nM) or CME from DU145
C
andDU145KD cultures induced CD73 expression (Figure 5
(a)). To determine if it was exosomal PGE2 that was indu-
cing the effect, DC were treated with PGE2 receptor
antagonists before being cultured with exosomes
(Figure 5(b)) at a concentration established previously
[19]. Two out of four PGE2 prostanoid receptors, EP2
and EP4, that had been shown to be present on DC [20]
were inhibited before the addition of exosomes to DC.
PGE2 receptor inhibition resulted in a significantly reduced
CD73 induction compared with the control (DMSO),
suggesting that exosomal PGE2 is a major contributor to
CD73 induction on DC (Figure 5(b)).
To confirm that PGE2 is associated with tumour
exosomes, a size exclusion chromatographic approach
was used to separate vesicles, present in cell culture
medium, from non-vesicular proteins (Figure 5(c)).
This was carried out using commercially available,
ready-made Exo-Spin Midi Columns. A proportion of
each fraction was assayed for protein using the micro-
BCA assay (Figure 5(c), i). This revealed a small protein
peak at around fractions 8–12, and a larger peak there-
after. Another proportion of each fraction was directly
coupled to protein-binding ELISA plates and stained for
the tetraspanin CD81, which is also an exosome marker.
A strong signal at fractions 7–13 for CD81 was observed
while the signal when using an isotype control was
negligible (Figure 5(c), i). The results were in agreement
with previously published data from our group showing
that vesicle-associated markers, such as CD81, CD9 and
CD63, precede fractions containing the bulk of the
proteins [21]. Based on the protein and CD81 results,
aliquots were combined from fractions 1–6 (pre-exoso-
mal fractions), fractions 7–14 (exosomal fractions) and
fractions 15–21 (post-exosomal fractions) (Figure 5(c),
ii). A proportion of the pre-exosomal, exosomal and
post-exosomal fractions were then assayed in a PGE2
competitive enzyme immunoassay. The majority of
PGE2 detected in the DU145 cell supernatant was
detected within the exosomal fractions (Figure 5(c), ii),
although a significant portion was also present in the
post-exosomal fractions. Assessment of individual frac-
tions from the exosomal fractions (7–14) revealed that
the concentration of PGE2 co-localized with the CD81
signal, highlighting a strong association of PGE2 to
exosomal vesicles (Figure 5(c), iii).
Adenosine inhibits T cell function
DC constitutively express CD39, an ectonucleotidase
responsible for ATP-to-AMP hydrolysis, and CD73,
responsible for AMP-to-adenosine hydrolysis. We
hypothesized that CD39+CD73+ DC sequester pro-inflam-
matory ATP from the tumour microenvironment and
replace it with immunosuppressive adenosine. First we
tested if adenosine inhibits the function of the 5T4-specific
CD8+ T cells. Titration of the adenosine analogue NECA
was carried out on T cells before stimulation with peptide-
pulsed DC for 6 h. IFNγ production by the T cells was
reduced in the presence of NECA in a dose-dependent
manner, reaching significance at 2 µM (Figure 6(a)), indi-
cating the adenosine sensitivity of effector T cells. Next, to
investigate theDC-mediated adenosine effect in ourmodel,
ATP was added to exosome-treated DC for 30 min before
being stimulated with LPS and IFNγ overnight. The results
of TNFα and IL-12 intracellular cytokine staining showed
that exosome-treatedDC in the presence of ATP produced
significantly less TNFα and IL-12 than DC without exo-
some exposure (Figure 6(b), i and ii). However, a small but
significant decrease in IL-12 production by exosome-trea-
ted DC not cultured with ATP was also observed (Figure 6
(a), ii), which may owe to a greater sensitivity of IL-12
production to adenosine due to the presence of residual
ATP. To prove that the ultimate effect on T cells was due to
adenosine, 5T4 specific CD8+ T cells were pre-treated with
an adenosine A2A receptor inhibitor before stimulation
with 5T4 peptide-pulsed DC, treated with or without exo-
somes, in the presence of AMP (Figure 6(c)). To ensure we
only investigatedCD73 activity due to its expression onDC
and not T cells, a CD73 inhibitor was added the T cells.We
also included a group of DC where CD73 induction by
exosomal PGE2 was inhibited with the EP4 receptor inhi-
bitor. T cell responses were significantly reduced when
AMP was added to exosome-treated DC but were partially
rescued by adding the EP4 inhibitor. However, in the
presence of the A2A adenosine receptor inhibitor, AMP
had no inhibitory effect on T cell responses, providing
evidence for adenosine-mediated inhibition. Taken
together, the results show that exosome-treated DC sup-
press T cell function in an adenosine-dependent manner.
Discussion
The present study reveals that tumour exosomes inhibit
CD8+ T cell responses when tumour-associated antigen is
cross-presented by DC. We inhibited exosome secretion
by knocking down Rab27a in DU145 prostate cancer cells.
When these cells were added to a tumour antigen cross-
presentation model, improved IFNγ production was
observed by 5T4 tumour-antigen-specific CD8+ T cells.
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This effect was reversible when purified exogenous exo-
somes were added together with DU145KD cells to DC.We
identified exosomal PGE2 as a significant inducer of CD73
expression on DC, triggering adenosine-mediated immu-
nosuppressive effects.Whilst Rab27a knockdown results in
a major attenuation (66%) of vesicle secretion from the
DU145 cells, it does not fully abrogate it, leaving a
population of vesicles remaining. We do not know
whether or not this remainder sub-population also carries
PGE2 and will also impair cross-presentation like the wild
type and complete vesicle population. If indeed this is the
case, they remain insufficient in number following
Rab27a-knockdown to achieve an effective immune-sup-
pressing dose. We clearly present evidence that
a
b
c
Figure 5. Exosomal PGE2 is a major trigger to induce CD73 expression on DC. (a) DC were treated for 24 h with PGE2 (50 nM) or
DU145C and DU145KD CME. (b) DC were pre-treated for 30 h with inhibitors of the EP2 and EP4 PGE2 receptors before being cultured
with CME from the cell lines. Raw data are shown as symbols. Means + SE of CD73 expression are also shown. (c) Size exclusion
chromatography to separate vesicles present in cell culture medium from non-vesicular proteins. (i) 30 fractions of DU145 cell
supernatants were assessed for protein concentration using a BCA assay or for CD81 in an ELISA assay. TRF values from single
measurements are shown. Representatives of two experiments are shown. (ii) Co-localization of the exosome marker CD81 and PGE2
in pooled fractions as indicated. (iii) Detailed co-localization assay in the individual fractions of the exosome-zone. *p < 0.05,
**p < 0.01, ***p < 0.001.
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perturbation of secretion through knockdown of Rab27a is
sufficient to remove enough suppressive vesicles from the
system, and to restore cross-presentation function. The
results demonstrate an important and dominantly negative
role for vesicles in this context.
As we have reported previously, irradiated DU145
cells are more effective in cross-priming T cells than
non-irradiated tumour cells, primarily due to the
translocation and cell surface expression of Hsp70 and
enhanced expression of 5T4 [13]. The presence or
absence of exosomes did not alter the efficiency of
cross-presentation from irradiated tumour cells. A
potential explanation of this observation is that stress
conditions experienced by tumour cells are reflected in
the exosomes they release [22–24]. Radiation of DU145
cells may generate exosomes carrying immune-activating
Hsp70, as observed in heat-shocked or chemotherapy-
treated tumour cells [24,25]. This would suggest that
radiation impacts on the quality of tumour exosomes,
potentially altering their dominant immunosuppressive
nature. This is a question currently being investigated in
our laboratory.
However, T cell cross-priming by non-irradiated
tumour cells was influenced by the presence of tumour
a b
c
Figure 6. Adenosinergic suppression of T cell and DC function by exosomes. (a) T cell line: 5T4-specific responses to DC+peptide
stimulation in the presence or absence of NECA. % IFNγ-producing T cells, determined by flow cytometry. (b) Percentage of DC that
produce TNFα (i) or IL-12 (ii) following LPS and exosome treatment in the presence or absence of ATP. Raw data are shown as
symbols. Means and SE are also shown. Representatives of two repeated experiments are shown. (c) 5T4 peptide-pulsed DC, treated
with/without exosomes and PGE2 receptor inhibitor (PGE2Ri) for 24 h, were incubated with AMP (0 or 200 µM) for 20 min before
being co-cultured with 5T4-specific T cells. A2A receptor inhibitor (A2ARi) was added and cytokine flow cytometry carried out after
overnight incubation. Means + SE % of IFNγ+ CD8+ T cells are shown from triplicate cultures. *p < 0.05, **p < 0.01, ***p < 0.001.
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exosomes in a dose-dependent manner. T cell responses
improved when exosome release was inhibited, highlight-
ing the predominant immunosuppressive effect of tumour
exosomes. Although tumour-derived exosomes have been
reported to generate antitumour immune responses in
several murine tumour models [11,12,26,27], our results
strongly suggest that, even if antigen is delivered by exo-
somes to DC, exosomal immunosuppressive effects over-
ride the potential antigen-delivery function. Indeed a
clinical trial, with tumour-derived exosomes as a cancer
vaccine in 40 patients with colorectal cancer, found no
clinical benefit [28], which may reflect the immunosup-
pressive properties of tumour exosomes.
In this study, we have demonstrated that exosomes
suppress the ability of CD4+ T cells to produce IL-2 upon
TCR activation, confirming previous results [9].
However, we found no direct exosomal inhibition of IL-
2 production by CD8+ T cells. This may be due to differ-
ent T cell subset sensitivity to exosomes, as described
before. The lack of direct exosomal inhibition of CD8+
T cells suggested that it may be the antigen-presenting
cells, i.e. the DC, that are affected by exosomes in this
model. It has been previously shown that exosomes inhi-
bit the differentiation of monocytes to DC [4,29] and also
have an inhibitory effect on DC maturation and cytokine
production [30]. DU145 exosomes induced DC to
express CD73 on their surface. To our knowledge, this
is the first study to assess the expression of this immuno-
suppressive marker on DC exposed to tumour exosomes.
CD73 is expressed on lymphocytes, endothelial cells and
epithelial cells but not on normal human monocytes,
macrophages or DC. CD73 is also expressed in several
types of human cancers; high expression of CD73 is
associated with a poor prognosis in colorectal cancer
[31] and triple negative breast cancer [32]. The observed
change in DC phenotype creates a subpopulation of DC
expressing both CD39 and CD73, whichmakes these cells
uniquely able to hydrolyse ATP to adenosine in the
pericellular milieu. It has been shown that under normal
conditions adenosine has direct tumour-promoting,
angiogenic and metastasis-inducing effects, and it is also
a powerful inhibitor of antitumour immune effector cells
in the tumour microenvironment [33,34]. It also impairs
maturation and function of dendritic cells [35]. Addition
of ATP to exosome-treated DC significantly reduced the
ability of DC to produce proinflammatory cytokines
TNFα and IL-12. Both cytokines are beneficial for enhan-
cing numerous antitumour effects and support the
maturation of DC and activation of T cells.
PGE2 is a lipid mediator that elicits a wide range of
biological effects associated with inflammation and can-
cer [36]. Although exosomal PGE2 expression has not
been studied in detail, the PGE2 content of exosomes
was found to correlate with the frequency of myeloid-
derived suppressor cells in mice [5]. We show here that
PGE2 is found predominantly in the exosomal fraction of
the supernatant of DU145 cells. Inhibition of the PGE2
receptors EP2/EP4 on DC significantly inhibited exo-
some-inducedCD73 expression, suggesting ligand-recep-
tor binding between exosomal PGE2 and DC. PGE2 is
necessary for the upregulation of CCR7 and metallopro-
teinase 9 on DC and their consequent migration into
lymph nodes [37,38]. However, PGE2 is also one of the
prominent inducers of IDO1 expression on DC resulting
in the attraction and induction of Tregs and consequent
inhibition of CD8+ T cell responses [39]. Our data high-
light how exosomal PGE2 induces CD73 expression on
DC with a significant impact on cytokine production and
T cell activation.
Lastly, assessment of T cell responses in this study
demonstrated that exosome-treated DC suppress T cell
function in an adenosine-dependent manner in the pre-
sence of extracellular ATP or AMP. Inhibition of the A2A
adenosine receptor on T cells alleviated the immunosup-
pression of 5T4-specific T cell responses in our experi-
mental setting. This is in agreement with other studies that
have shown that signalling via the A2A receptor inhibits
pro-inflammatory cytokine production by T cells and sup-
presses CD8+ cytolytic activity [40,41].
Taking all this together, we have demonstrated here
that prostate-cancer-derived exosomes suppress tumour
antigen cross-presentation via the induction of CD73
expression on DC. We also reveal a hitherto unknown
effect of tumour exosomes on the suppression of DC
function via exosomal PGE2, adding a new element to
tumour exosome–immune cell cross-talk.
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